AzTrials
AzTrials

Alzheimer DiseaseCEDARNCT03687710

The Comparative Effectiveness Dementia & Alzheimer's Registry

An observational study of Alzheimer Disease and Mild Cognitive Impairment, run by Weill Medical College of Cornell University at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

To evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care. Read more about this study

Who is it for?
Ages 18 to 99 yearsHealthy volunteers can take part
Conditions the study is for
Alzheimer Disease, Mild Cognitive Impairment
What is being tested?
Multidomain precision medicine intervention
How many people
452 participants
Where
1 siteUnited States
Study dates
16 Feb 2015to 30 Jun 2028
How long will I take part?
10 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Male and female patients will be recruited at the Alzheimer's Prevention Clinic, Weill Cornell Medicine Memory Disorders Program.

Who may be able to join

  • 18 years of age or older
  • family history of Alzheimer's disease and no cognitive complaints OR subjective cognitive decline OR preclinical AD OR mild cognitive impairment due to AD or other conditions

Who cannot join

  • none

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site

  • Weill Cornell Medicine

    New York, New York, 10021

Other trials in United States

About this study

To evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care.

Read the detailed description

The Comparative Effectiveness Dementia \& Alzheimer's Registry (CEDAR) Project is a prospective, observational registry of adult patients at-risk for, or with, a diagnosis of dementia due to Alzheimer's disease (AD) or other neurodegenerative dementias. The purpose of this study is to develop a research repository, or database, for information collected during routine medical care of people with normal memory and family history of AD, or with memory loss or other changes in thinking. The registry will help generate empirical evidence that improves knowledge and informs care decisions about risk reduction for dementia due to AD, and about the effectiveness of a clinical precision medicine intervention. Using a life course approach to comparative effectiveness research will enable investigators to analyze the effects of evidence-based multidomain interventions on cognition, biomarkers of AD risk, and calculated AD risk across the pre-dementia spectrum of AD.

Being tested
Multidomain precision medicine intervention
Medical subject headings
Alzheimer Disease, Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multidomain precision medicine interventionBehavioural

    Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months

    Composite Cognitive Battery (including NIH Toolbox Cognition Battery and other pen-and-paper neuropsychological tests).

    Measured: every 6 months, for 18 months

Secondary outcomes (10)

  1. Change from Baseline in Cognitive Aging Composite (CAC) every 6 months

    Composite Cognitive Battery, including neuropsychological tests related to non-pathological (age-related) cognitive decline.

    Measured: every 6 months, for 18 months

  2. Change from Baseline of Australian National University - Alzheimer's Disease Risk Score (ANU-ADRI) at 6 months

    Measure longitudinal changes in a validated Alzheimer's risk scale (score range from -13 to 78) where higher scores confer higher risk

    Measured: 6 months

  3. Change in Baseline on Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score at 18 months

    Measure longitudinal changes in a validated Alzheimer's risk scale (score range from 0 to 14) where higher scores confer higher risk

    Measured: 18 months

  4. Change from Baseline on American College of Cardiology / American Heart Association Cardiovascular Risk Percentage at 18 months

    Measure longitudinal changes in a validated cardiovascular risk scale (higher percentage confers higher risk).

    Measured: 18 months

  5. Change from Baseline on Multi-Ethnic Study of Atherosclerosis (MESA) Risk Percentage at 18 months.

    Measure longitudinal changes in a validated cardiovascular risk scale (higher percentage confers higher risk).

    Measured: 18 months

  6. Change from Baseline in Cholesterol Biomarkers at 18 months

    Change in blood serum levels of cholesterol (total, LDL, HDL) in mg/dL

    Measured: 18 months

  7. Change from Baseline in Inflammatory Biomarkers at 18 months

    Change in blood serum levels of hs-CRP, fibrinogen, Cystatin C in mg/dL

    Measured: 18 months

  8. Change from Baseline in Metabolism Biomarkers at 18 months

    Change in blood serum levels of HbA1c and HOMA-IR

    Measured: 18 months

  9. Change from Baseline in Homocysteine at 18 months

    Change in blood serum level of homocysteine

    Measured: 18 months

  10. Change from Baseline in Vitamin D at 18 months

    Change in blood serum level of Vitamin D

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Sep 2018
  2. Study start16 Feb 2015
  3. Primary completion30 Jun 2028 (estimated)
  4. Study completion30 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
452 participants (estimated)
Target duration
10 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT03687710
Sponsor's protocol ID
1408015423
Acronym
CEDAR
Status last verified
Mar 2026
First submitted
6 Sep 2018
Last updated
30 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Isaacson RS, Ganzer CA, Hristov H, Hackett K, Caesar E, Cohen R, Kachko R, Melendez-Cabrero J, Rahman A, Scheyer O, Hwang MJ, Berkowitz C, Hendrix S, Mureb M, Schelke MW, Mosconi L, Seifan A, Krikorian R. The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach. Alzheimers Dement. 2018 Dec;14(12):1663-1673. doi: 10.1016/j.jalz.2018.08.004. Epub 2018 Nov 13.

    PubMed 30446421

Questions about this trial

What is this clinical trial studying?

An observational study of Alzheimer Disease and Mild Cognitive Impairment, run by Weill Medical College of Cornell University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months (time frame: every 6 months, for 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03687710, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in